gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Tumor necrosis factor receptor superfamily, member 9

4-1BB, CD137, ILA
The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor contributes to the clonal expansion, survival, and development of T cells. It can also induce proliferation in peripheral monocytes, enhance T cell apoptosis induced by TCR/CD3 triggered activation, and regulate CD28 co-stimulation to promote Th1 cell responses. The expression of this receptor is induced by lymphocyte activation. TRAF adaptor proteins have been shown to bind to this receptor and transduce the signals leading to activation of NF-kappaB. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: CAN, CD8, CD4, CD28, OX40
Papers on 4-1BB
Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment.
Richmond et al., The Valley, Anguilla. In J Natl Cancer Inst, Jun 2016
Therapeutic response was queried in immunodeficient mice, in mice with CCL5-deficient tumors, and in mice cotreated with CD137 agonist to activate TILs.
Deciphering cd137 (4-1bb) signaling in T-cell costimulation for translation into successful cancer immunotherapy.
Melero et al., Pamplona, Spain. In Eur J Immunol, Feb 2016
UNASSIGNED: CD137 (4-1BB, TNF-receptor superfamily 9) is a surface glycoprotein of the TNFR family which can be induced on a variety of leukocyte subsets.
Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: Simultaneous measurement of NF-κB, NFAT and AP-1.
Steinberger et al., Vienna, Austria. In J Immunol Methods, Feb 2016
In these experiments we could show that engagement of the costimulatory molecule 4-1BB enhances NF-κB and AP-1 activity, whereas coinhibition via PD-1 or BTLA strongly reduced the activation of NF-κB and NFAT.
Dysfunctional subcutaneous fat with reduced Dicer and brown adipose tissue gene expression in HIV-infected patients.
Grinspoon et al., Bethesda, United States. In J Clin Endocrinol Metab, Feb 2016
CD137 (P=0.008)] and other genes [DIO2 (P=0.002),
Cell-Autonomous Brown-Like Adipogenesis of Preadipocytes from Retinoblastoma Haploinsufficient Mice.
Ribot et al., Palma, Spain. In J Cell Physiol, Feb 2016
Primary white Rb(+/-) adipocytes displayed under basal conditions increased glucose uptake and an enhanced expression of brown adipocyte-related genes (Pparg, Ppargc1a, Ppargc1b, Prdm16, Cpt1b), but not of purported beige/brite transcriptional markers (Cd137, Tmem26, Tbx1, Slc27a1, Hoxc9, Shox2).
Rationale for anti-CD137 cancer immunotherapy.
Kohrt et al., Stanford, United States. In Eur J Cancer, Feb 2016
One such strategy with promising clinical applications is the targeting of CD137, a member of the tumour necrosis factor receptor superfamily.
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells.
Sadelain et al., New York City, United States. In Cancer Cell, Nov 2015
Using an in vivo "stress test" to challenge CD19-targeted T cells, we studied the functionality and persistence imparted by seven different CAR structures providing CD28 and/or 4-1BB costimulation.
Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS.
Melero et al., Pamplona, Spain. In Semin Oncol, Aug 2015
Co-stimulatory receptors include surface moieties that are constitutively expressed on resting lymphocytes such as CD28 or CD27 and others whose expression is induced upon recent previous antigen priming, ie, CD137, GITR, OX40, and ICOS.
The pharmacology of second-generation chimeric antigen receptors.
Sadelain et al., New York City, United States. In Nat Rev Drug Discov, Jul 2015
CD19-targeted CARs that incorporate CD28 or 4-1BB signalling domains are the best known to date.
Is CD137 Ligand (CD137L) Signaling a Fine Tuner of Immune Responses?
Kwon, Ulsan, South Korea. In Immune Netw, Jun 2015
Now, it has been being accepted that reverse signaling through CD137 ligand (CD137L) plays an important role in vivo during hematopoiesis and in immune regulation.
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.
Mackall et al., Bethesda, United States. In Nat Med, Jun 2015
We further determine that CD28 costimulation augments, whereas 4-1BB costimulation reduces, exhaustion induced by persistent CAR signaling.
Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.
Hinrichs et al., Bethesda, United States. In J Clin Oncol, Jun 2015
The HPV reactivity of T cells in the infusion product (as measured by interferon gamma production, enzyme-linked immunospot, and CD137 upregulation assays) correlated positively with clinical response (P = .0238
Characteristics of immunosuppressive regulatory T cells in cutaneous squamous cell carcinomas and role in metastasis.
Healy et al., Southampton, United Kingdom. In Lancet, Mar 2015
SCC Tregs expressed significantly higher levels of the co-stimulatory molecules OX40 (37·2% of FOXP3+ cell population, n=10 tumours) and 4-1BB (12·6%, n=9) than peritumoral non-regulatory T cells and Tregs from peripheral blood and normal skin (p=0·0005).
Tim-3 and Tim-4 as the potential targets for antitumor therapy.
Ruan et al., Chongqing, China. In Hum Vaccin Immunother, 2014
Moreover, co-blockage of Tim-3 and PD-1, Tim-3 and CD137, Tim-3 and carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) could enhance cell-mediated immunity in advanced tumor, and combined treatment with anti-Tim-3 and anti-Tim-4 mAbs further increase the efficacy of cancer vaccines.
Comparison of cytokine expressions in acute myocardial infarction and stable angina stages of coronary artery disease.
Ding et al., Shanghai, China. In Int J Clin Exp Med, 2014
RESULTS: Compared with SA patients and the controls respectively, in AMI patients, IFNα2, IFNαR1, IFNαR2, IFNγR1, IFNγR2, L1β, IL16, IL18, Cxcl1, Cxcl2, Cxcl6, CxcR2, CxcR4, LIGHT, TNFR1, LT-βR, CD137, TRAILR, and TWEAKR mRNA expressions were significantly up-regulated (P<0.05), while Ccl5, Ccl24, Ccl28, CcR5, TWEAK, CD40, CD27, and BAFFR mRNA expressions were significantly down-regulated (P<0.05).
CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications.
Natkunam et al., Stanford, United States. In Am J Pathol, 2012
CD137 protein is expressed by a select group of hematolymphoid tumors, including classical Hodgkin lymphoma, T-cell and NK/T-cell lymphomas, and follicular dendritic cells neoplasms.
CD137 on inflamed lymphatic endothelial cells enhances CCL21-guided migration of dendritic cells.
Rouzaut et al., Pamplona, Spain. In Faseb J, 2012
treatment with CD137 agonistic antibody induces CCL21 expression and DC accumulation close to lymphatic vessels. Collectively, our results demonstrate that the inflammatory function of lymphatic vessels can be regulated by CD137.
CD137 deficiency does not affect development of airway inflammation or respiratory tolerance induction in murine models.
Hansen et al., Hannover, Germany. In Clin Exp Immunol, 2012
deficiency does not affect development of airway inflammation or respiratory tolerance induction
Tumor-mast cell interactions: induction of pro-tumorigenic genes and anti-tumorigenic 4-1BB in MCs in response to Lewis Lung Carcinoma.
Pejler et al., Uppsala, Sweden. In Mol Immunol, 2012
conditioned medium from Lewis Lung Carcinoma cells caused significant upregulation of 4-1BB in mast cells
Assessment of activity of an adhesion molecule CD134 and CD137 in colorectal cancer patients.
Kędra et al., Białystok, Poland. In Pol Przegl Chir, 2011
CD137 activity is directly proportional to colorectal cancer stage. Surgical resection of the tumor results in increased CD134 and CD137 expression
share on facebooktweetadd +1mail to friends